Qureight

Deep-learning analysis of chest CT and other scans for drug trials in lung fibrosis and other lung and heart diseases, now building a 3D chest-imaging foundation model to cut the data needed for each new disease model. Runs trials for AstraZeneca and Bristol Myers Squibb. $20m Series B led by Molten Ventures.